Human Apolipoprotein A‑I/ApoA1 Antibody

Apolipoprotein A‑I/ApoA1 in HepG2 Human Cell Line.

Apolipoprotein A-I/ApoA1 was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using Rabbit Anti-Human Apolipoprotein A-I/ApoA1 Monoclonal Antibody (Catalog # MAB36641) at 1 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Apolipoprotein A‑I/ApoA1 in Human Liver Cancer Tissue.

Apolipoprotein A-I/ApoA1 was detected in immersion fixed paraffin-embedded sections of human liver cancer tissue using Rabbit Anti-Human Apolipoprotein A-I/ApoA1 Monoclonal Antibody (Catalog # MAB36641) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of Apolipoprotein A-I/ApoA1 by Western Blot

Particle number increases proportionally with needle-to-processing time. (a) A set of four peripheral blood samples was each collected in n=4 biological replicates Streck Cell-Free DNA BCT. EV enrichment was performed by differential ultracentrifugation (dUC), followed by SEC. EV-enriched fractions were analyzed by NTA, BCA and WB. (b) Particle numbers obtained from the different needle-to-processing times, measured by NTA. Data normalized to the control condition of immediately processed blood. Mean of normalized value is displayed for each needle-to-processing time and statistical significance is assessed using one sample t test (Bonferroni-Holm-adjusted p-values) with *p=0.0175 (24 h), **p=0.0033 (72 h) and **p=0.0033 (1 week). (c) Median size of particles recovered in EV-enriched fractions from the different needle-to-processing times. Mean value is displayed for each needle-to-processing time and statistical significance is assessed using paired t test (Bonferroni-Holm-adjusted p-values) with **p=0.0014 (24 h vs. immediate processing), ***p=0.0006 (72 h vs. immediate processing) and ***p=0.0006 (1 week vs. immediate processing). In (b) and (c) symbols signify independent biological replicates. (d) Representative immunoblotting image to characterize particles obtained according to EV markers, cell-specific markers and apolipoprotein markers. Original blots are presented in Supplementary Fig. S10 online. (e)-(g) Quantification of band intensities in (d). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40624148), licensed under a CC-BY license. Not internally tested by R&D Systems.